Drugs / humanized CD19 CAR-T Cells with TLR2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07335094 | Jun 2026 → Jun 2028 expected | B-cell acute lymphoblastic leukemia | Zhujiang Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | humanized CD19 CAR-T Cells with TLR2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07335094 ↗ |
| Modality | Cell therapy | “humanized CD19 CAR-T therapy” NCT07335094 ↗ |
| Target | CD19 | “humanized CD19 CAR-T” NCT07335094 ↗ |